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PROMISING OUTCOMES WITH TANDEM AUTOLOGOUS STEM CELL
RESCUE IN ‘LATE’ WILMS TUMOR RELAPSE
Chaudhury, S., Merchant, N., Tse, W., Duerst, R., Schneiderman, J.,
Morgan, E., Kletzel, M. Childrens Memorial Hospital, Northwestern
University’s Feinberg School of Medicine, Chicago, IL
Introduction: Optimal management of relapsed Wilms’ tumor
(WT) patients remains unclear. Modern second-line treatment
consists of either salvage chemotherapy6radiation therapy or
chemotherapy followed by high-dose chemotherapy and autologous
hematopoietic stem cell rescue (HD-ASCR).
Methods:Fifteen consecutive patients with relapsed/ persistentWT
from 2001-09, enrolled on IRB protocol with planned two tandem
cycles of HD-ASCR. Myeloablative chemotherapy regimen for first
cycle consisted of Etoposide 2400 mg/m2, Carboplatin 2000 mg/
m2, Cyclophosphamide 3600 mg/m2; and Melphalan 180 mg/m2
and cyclophosphamide 4500 mg/m2 for the second.
Results: There were 6 males and 9 females with a median age at di-
agnosis of 4.6 y(range 3-16 y), and median time from diagnosis to re-
lapse 1 y (range 0.1- 7.5 y). Median time from relapse to HD-ASCR
was 5m (range 3-31 m). Histology was favorable in 12 and anaplastic
in three. Five of 15 patients received HD-ASCR for early relapse/
refractory disease within 6 months from diagnosis. Ten patients
received planned two cycles of HD-ASCR while the remaining 5 re-
ceived only 1 course of HD-ASCR due to disease progression or tox-
icity. Disease state at the time of HD-ASCRwas CR in 7, VGPR in 5
and PR in 3. Post- ASCR, median time to neutrophil engraftment
and unsupported platelet count .20 K was 12 and 21 days, respec-
tively. Regimen related toxicity included infections (1 aspergillus, 1
klebsiella), hemorrhagic cystitis (1) and one fatal case of acute renal
failure. At a median follow-up of 60 months, nine patients are alive
and disease free. Six patients died from disease relapse in five and re-
nal failure prior to engraftment in one. Five patients with refractory
disease/early relapse (#6 months from initial diagnosis) before un-
dergoing HD-ASCR had significantly worse outcomes from relapse.
(p 5 0.001). The 5 year estimated event-free survival (EFS) and the
overall survival (OS) in the remaining ‘late’ relapsed patients are 55%
and 75% respectively. There was no correlation of outcomewith dis-
ease stage at diagnosis, site of relapse, disease state at ASCR-HD.
Conclusions: Tandem HD-ASCR remains an effective, non-toxic
treatment for patients with relapsed Wilms’ tumor especially
if greater than 6 months from diagnosis. Patients with persistent
disease or early relapse within 6 months from diagnosis likely have
different biological characteristics and should receive a novel modal-
ity of therapy.
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AUTOLOGOUS STEM CELL TRANSPLANT FOR ADVANCED STAGE PEDIAT-
RIC SOLID TUMORS
Hutspardol, S.1, Pakakasama, S.2, Sirachainan, N.2, Anurathapan, U.2,
Hongeng, S.2 1Srinakharinwirot University, Nakorn Nayok, Thailand;
2Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Autologous stem cell transplant (ASCT) potentially promotes the
survival in high-risk pediatric solid tumors. Individual preparative
regimen for each primary solid tumor is not yet determined owing
to various conditions of disease status and previous treatment. We
have transplanted 17 patients with advanced stage solid tumors using
two different preparative regimens. Primary diagnosis included 10
patients (58.9%) with neuroblastoma stage 3 and 4, 2 patients
(11.7%) with Wilms tumor stage 4, 2 patients (11.7%) with germ
cell tumor stage 3 and 4, one each patient with stage 4 rhabdomyo-
sarcoma (5.9%), Ewing’s sarcoma (5.9%), and retinoblastoma
(5.9%). Indication for ASCT was tumor recurrence in 7 patients
(50%) and residual disease in 7 patients (50%). Eleven patients
(65%) with previously treated high-dose cyclophosphamide received
regimen 1 consisting of carboplatin, etoposide, and melphalan dur-
ing conditioning. Regimen 2 (carboplatin, etoposide, cyclophospha-
mide) was chosen for 6 patients (35%) without previous treatment of
high-dose cyclophosphamide. Most patients achieved engraftment
within a median time of 11 days (range 7-18 days). There were 5 pa-tients who alive and disease-free at the end of study. Median follow-
up among survivors was 4.1 years (range 1.2-6.3 years). Disease pro-
gression-free survival (PFS) at 1- and 3-year post-ASCT was 47%
and 32%. Overall survival (OS) at 1-, 3-, and 5-year post-ASCT
was 71%, 36%, and 18%. There was no significant difference in
PFS and OS between two different transplant regimens in univariate
analysis (p 5 0.36 and p 5 0.62). Likewise, there was no significant
difference in PFS andOS between two indications of ASCT (residual
disease and tumor recurrence; p5 0.37 and 0.50), time from diagno-
sis to ASCT (\1 year and$ 1 year; p5 0.72 and 0.24), and primary
diagnosis (neuroblastoma and non-neuroblastoma; p 5 0.75 and
0.87). No severe transplant-related toxicity and mortality was ob-
served herein. Due to limited number of patients in both regimens,
continuing investigation of ASCT role as salvage therapy for ad-
vanced solid tumors should be carried on.
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HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION EN-
HANCES ANTI-TUMOR ACTIVITY AGAINST RENAL CELL CANCER
Budak-Alpdogan, T., Sauter, C., Bailey, C., Biswas, C., Panis, M.,
Civriz, S., Alpdogan, O. Kimmel Cancer Center, Thomas Jefferson Uni-
versity, Philadelphia, PA
AllogeneicHSCThas been suggested as a treatment option for cy-
tokine unresponsive, advanced renal cell cancer (RCC). However,
tumor progression remains as the main problem post-transplant.
We hypothesize that haploidentical (HI)HSCTmight enhance graft
versus tumor (GVT) activity against RCC and improve the outcome
after transplant by tumor growth suppression. We first established
a HI-transplant model using two different hybrid mouse strains as
donor and recipient in the experiments. Lethally irradiated
(CB6F1-(H2Kb/d) recipients were transplanted with T cell-de-
pleted (TCD) bone marrow (BM) from B6CBAF1 (H2Kb/k). We
found that B6CBAF1 TCD-BM cells engrafted well in recipients
of HI-HSCT without graft failure when analyzed at varying time
points after the transplant.
We then exploredGVTactivity in thisHI-HSCTmodel. Lethally
irradiatedCB6F1 host were transplantedTCD-BM from the follow-
ing donors; B6D2F1 (H2Kb/d), B6 (H2Kb), and B6CBAF1 (H2Kb/
k). Animals received RENCA cells on the same day of the transplant.
Low doseT cell (1x105) infusionwas enough to elicit GVT effect but
not GVHD and to provide murine RCC growth control and survival
advantage in HI- HSCT. Recipients of HI-HSCT BM and T cells
showed better anti-tumor activity than recipients of B6D2F1 or B6
BM +TCells, respectively. Recipients of HI-HSCTBM and T cells
did not reveal any tumor development in the first 50 days, and had
a significantly better survival compared to other groups. Low dose
haploidentical CD8+ T cells provided a better anti-tumor activity
than CD4+ T cells but unseparated T cells resulted in significantly
better survival than either subset alone. We concluded from this ex-
periment that GVT activity against to RENCA cells is mainly driven
by CD8+ T cells but they need CD4+ T cells help for optimal anti-
tumor activity.
Our data suggested that HI-HSCT could provide substantial
graft-versus-tumor effect against renal cell carcinoma that might
suppress tumor growth and elicit survival advantage.STEM CELL BIOLOGY461
HUMAN UMBILICAL CORD BLOOD (HUCB) DERIVED STEM CELLS EN-
HANCES WOUND HEALING
Liao, Y.1, Itoh, M.2, Roberts, S.1, Highet, A.M.1, Yang, A.1,
Christiano, A.2, Cairo, M.S.1 1New York Medical College, Valhalla,
NY; 2Columbia University, New York, NY
Background:Recessive dystrophic epidermolysis bullosa (RDEB) is
a severe inherited skin blistering disease caused by mutations in Co-
l7a1gene, which encodes a major component in anchoring fibrils
(Christiano et.al. Nat Gen 1993). An initial report has shown prom-
ises of Allogeneic (Allo) -SCT for the treatment of RDEB (Wagner
et.al.NEngl JMed 2010). However no distinct anchoring fibrils were
observed in the recipient skin and the functional cell populations areS373
